PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 14738913

Integrated high capacity solid phase extraction-MS/MS system for pharmaceutical profiling in drug discovery.

Edward H Kerns·Teresa Kleintop·David Little·Thomas Tobien·Larry Mallis·Li Di·Mei Hu·Yan Hong·Oliver J McConnell
View original source ↗Export metadata ↓

Abstract

A method is described for use in analysis of samples from pharmaceutical profiling of early drug discovery compounds. The method consists of a high capacity autosampler which injects samples into one of two solid phase extraction columns operated in parallel for alternating trapping, washing and elution into a tandem quadrupole mass spectrometer operated in multiple reaction monitoring (MRM) MS/MS mode. A primary method, which is useful for 80-90% of compounds, and a secondary method, which is useful for a majority of the remaining compounds, are described. No analytical HPLC column is used and the analysis rate is approximately 50 samples/h. Specificity is obtained using MRM analysis. Application of the method for high capacity analysis of metabolic stability samples is described.

Explore related subjects

Drug DesignDrug StabilityMass SpectrometryPharmaceutical PreparationsTechnology, PharmaceuticalJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Edward H Kerns, Teresa Kleintop, David Little, Thomas Tobien, Larry Mallis, Li Di, Mei Hu, Yan Hong, Oliver J McConnell. 2004-01-27. Integrated high capacity solid phase extraction-MS/MS system for pharmaceutical profiling in drug discovery.. https://doi.org/10.1016/j.japna.2003.03.001

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Strategies to design pyrazolyl urea derivatives for p38 kinase inhibition: a molecular modeling study.

The p38 protein kinase is a serine-threonine mitogen activated protein kinase, which plays an important role in inflammation and arthritis. A combined study of 3D-QSAR and molecular docking has been undertaken to explore the structural insights of pyrazolyl urea p38 kinase inhibitors. The 3D-QSAR studies involved comparative molecular field analysis (CoMFA) and comparative molecular similarity indices (CoMSIA). The best CoMFA model was derived from the atom fit alignment with a cross-validated r (2 )(q (2)) value of 0.516 and conventional r (2) of 0.950, while the best CoMSIA model yielded a q (2) of 0.455 and r (2) of 0.979 (39 molecules in training set, 9 molecules in test set). The CoMFA and CoMSIA contour maps generated from these models provided inklings about the influence of interactive molecular fields in the space on the activity. GOLD, Sybyl (FlexX) and AutoDock docking protocols were exercised to explore the protein-inhibitor interactions. The integration of 3D-QSAR and molecular docking has proffered essential structural features of pyrazolyl urea inhibitors and also strategies to design new potent analogues with enhanced activity.

Drug Design↗